New England Journal of Medicine retracts avacopan study used by FDA to assess efficacy

The New England Journal of Medicine has retracted its publication of the sole trial of avacopan used by the FDA to assess the drug’s efficacy before approving it for patients with ANCA-associated vasculitis.The retraction comes amid the FDA’s push to withdraw its approval of avacopan (Tavneos, Amgen), alleging that employees of the original manufacturer, ChemoCentryx, manipulated data